Across TCGA pan-cancer cohorts, CMTM4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMTM4 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CMTM4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMTM4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where CMTM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.486	0.926	<.001	29	view →
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	8	view →
LUAD	DFS	Median	II,III,IV	0.354	0.685	.027	6	view →
PDAC	OS	Tertile	II,III,IV	0.917	0.716	.009	5	view →
UCEC	OS	Tertile	All	1.000	0.897	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CMTM4 tumor-vs-normal RNA expression · all CMTM4 data types